Lung adenocarcinoma with a novel SRBD1-ALK Fusion responding to crizotinib

Objectives: ... Here, we reported a case of lung adenocarcinoma harboring a novel S1 RNA binding domain 1 (SRBD1)–ALK fusion which the breakpoints was (S6,A20). To our knowledge, this case is the first report showed clinical evidence of SRBD1-ALK fusion responding to crizotinib. Conclusion: To our knowledge, our case is the first case of SRBD1-ALK fusion with excellent response to crizotinib. This case merits further follow-up and provides valuable information on the response to crizotinib of NSCLC patients with SRBD1-ALK fusion. READ ARTICLE

Lung Cancer DOI:10.1016/j.lungcan.2020.04.031

Authors: Yao, Chen, Xiaochen Zhang, Qi Jiang, Bo Wang, Yina Wang, Yan Junrong

Case StudyKirk SmithAugust 1, 2020NSCLC, SRBD1-ALK, crizotinib, NGS

SRBD1-ALK, a Novel ALK Fusion Gene Identified in an Adenocarcinoma Patient by Next-Generation Sequencing

... Here, we report a case of adenocarcinoma harboring a novel S1 RNA binding domain 1 (SRBD1)–ALK fusion gene identified accidentally during routine molecular profiling by next-generation sequencing... Without any other oncogenic mutation detected, we speculate that the novel SRBD1-ALK fusion served as a driver mutation of the patient’s disease. And ALK TKIs might be effective in the treatment of tumors with this new fusion gene. READ ARTICLE

Journal of Thoracic Oncology DOI:10.1016/j.jtho.2018.11.027

Authors: Xue Hou, Huamin Xu, Likun Chen

Case StudyKirk SmithApril 1, 2019SRBD1-ALK, ALK Fusion, Adenocarcinoma, Next-Generation Sequencing